Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)

(June 12, 2018) – Sunovion Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for apomorphine sublingual film (APL-130277) to treat motor fluctuations experienced by people living with Parkinson’s disease. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is January 29, 2019. Read more…